Intra-Cellular Therapies Inc (BSP:I2TC34)
R$ 83.36 0 (0%) Market Cap: 53.03 Bil Enterprise Value: 47.40 Bil PE Ratio: 0 PB Ratio: 8.38 GF Score: 41/100

Q4 2020 Intra-Cellular Therapies Inc Earnings Call Transcript

Feb 25, 2021 / 01:30PM GMT
Operator

Good morning, ladies and gentlemen, and welcome to the Intra-Cellular Therapies Fourth Quarter and Year-end 2020 Financial Results Conference Call. (Operator Instructions) As a reminder, today's conference call is being recorded.

I would now like to turn the conference over to your host, Dr. Juan Sanchez, Vice President, Corporate Communications and Investor Relations. Please go ahead.

Juan Fernando Sanchez
Intra-Cellular Therapies, Inc. - VP of Corporate Communications & IR

Good morning, and thank you all for joining us for today's conference call. Our earnings press release provides a corporate update and details of the company's financial results for the fourth quarter and year ended December 31, 2020. This press release crossed the wire a short time ago and is available on our website at intracellulartherapies.com.

Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Mark Neumann, Executive Vice President and Chief Commercial Officer; Dr. Suresh Durgam, Senior Vice President and Chief Medical

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot